profit from every ₹100 of sales.
₹0₹100
Glenmark Pharmaceuticals
₹2,640.00-0.74% today
+34.9% in 1 year
1-year low ₹1,920.401-year high ₹2,677.20
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹54.71 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Glenmark Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from ₹114 billion in 2023 to ₹167 billion in 2026, with ₹13.6 billion of profit last year.
SalesProfit
Glenmark Pharmaceuticals handed back 7% of the cash it generated last year.
₹1.4B
Free cash flow 2026₹20.9B
Bought back its own shares–
Paid as dividends₹1.4B
Cash vs. debt₹11.7B vs. ₹5.9B
Glenmark Pharmaceuticals vs. similar companies
Glenmark Pharmaceuticals grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Glenmark Pharmaceuticals | 54.7× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Glenmark Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 114,319 | 116,355 | 131,458 | 167,114 | |
| 68,453 | 67,564 | 87,925 | 119,639 | |
| 10,789 | 6,311 | 18,654 | 39,989 | |
| 12,001 | 11,833 | 20,923 | 27,670 | |
| 2,972 | -15,017 | 10,471 | 13,619 | |
| 10.53 | -53.22 | 37.11 | 48.24 | |
| 59.9% | 58.1% | 66.9% | 71.6% | |
| 9.4% | 5.4% | 14.2% | 23.9% | |
| 2.6% | -12.9% | 8.0% | 8.1% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 193,717 | 143,586 | 160,496 | 199,079 |
| Cash | 11,592 | 16,583 | 16,757 | 11,747 |
| Total debt | 46,079 | 12,309 | 24,727 | 5,935 |
| Total liabilities | 95,324 | 65,111 | 72,005 | 93,961 |
| 94,739 | 78,479 | 88,494 | 105,121 | |
| 282 | 282 | 282 | 282 | |
| 3.1% | 4.6% | 10.6% | 14.8% | |
| 3.1% | -19.1% | 11.8% | 13.0% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 6,254 | -2,654 | -8,276 | 34,450 | |
| 6,078 | 8,984 | 7,507 | 13,577 | |
| 176 | -11,638 | -15,783 | 20,873 | |
| Dividends paid | 1,366 | 1,178 | 704 | 1,410 |
| – | – | – | – | |
| 68 | 50 | -92 | 268 |
Valuation
- 54.7×
- –
- 0.83
- 7.2×
- 4.5×
- 35.7×
- 26.7×
- 2.8%
- 1.8%
- 0.2%
Profitability
- 71.6%
- 23.9%
- 8.1%
- –
- 14.8%
- 8.3%
- –
- –
- –
- –
Growth
- +13.5%
- +66.1%
- –
- –
- +0.0%
Financial health
- -0.2×
- 0.06
- –
- 10.5×
- 1.77
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 14%of 952
Top 16%of 883
Bottom 20%of 601
Top 41%of 888
Top 37%of 987
0.2%of the share price, paid each year
On $1,000 invested$2a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
10.4% of its profit
Room to growStretchedMore than it earns: 6.8%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
23No pass
Philip Fisher
66Pass
Peter Lynch
84Pass
Joel Greenblatt
11No pass
Charlie Munger
52No pass
Terry Smith
54No pass
Questions about Glenmark Pharmaceuticals
Is Glenmark Pharmaceuticals a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Glenmark Pharmaceuticals AI analysis
What does Glenmark Pharmaceuticals do?
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Mumbai, India.
Does Glenmark Pharmaceuticals pay a dividend?
Yes. At today's price the dividend is 0.2% a year, about 10% of its yearly profit. In 2026 it paid out ₹1.41 billion in dividends.
Is Glenmark Pharmaceuticals stock halal?
Yes. Glenmark Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
How has Glenmark Pharmaceuticals stock done over the past year?
Up 34.9% over the past twelve months, to ₹2,640.00. It traded between ₹1,920.40 and ₹2,677.20, close to its high.
Who are Glenmark Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Glenmark Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.